This inventor holds 8 USPTO granted patents and 1 published patent application and 3 EPO patents. Top assignee: Hoffmann-La Roche Inc.. Active years: 2009-2017.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2009-2017
Title: **Agnieszka Kowalczyk: Innovating Drug Delivery Through Integrin Antagonists**
Introduction
Agnieszka Kowalczyk, an accomplished inventor located in Mine Hill, NJ, has made significant strides in the field of drug delivery systems. With a total of eight patents to her name, her innovative work centers on the development of integrin antagonist conjugates, which have the potential to revolutionize targeted therapies.
Latest Patents
Agnieszka's latest patents include two notable inventions related to integrin antagonist conjugates. The first patent, titled "Integrin antagonist conjugates for targeted delivery to cells expressing LFA-1," focuses on compounds that facilitate the targeted delivery of conjugated moieties, including small molecules and peptides, specifically to cells expressing the LFA-1 integrin. This advancement holds promise for improved treatment efficacy in various medical applications.
The second patent, "Integrin antagonist conjugates for targeted delivery to cells expressing alpha-V-beta-3," also centers on compounds that allow for the targeted delivery of conjugates linked to alpha-V-beta-3 integrin antagonists. As with her previous invention, this patent aims to enhance the precision of drug delivery systems, making treatments more effective and reducing potential side effects.
Career Highlights
Agnieszka Kowalczyk is currently employed at Hoffmann-La Roche Inc., a leading biotechnology company known for its innovations in pharmaceuticals and diagnostics. Her work at the company has been instrumental in advancing strategies for targeted drug delivery, which plays a crucial role in modern therapeutics.
Collaborations
Throughout her career, Agnieszka has collaborated with esteemed colleagues, including Robert Alan Goodnow, Jr. and Achyutharao Sidduri. These partnerships have allowed her to leverage diverse expertise and further enhance the impact of her innovations.
Conclusion
Agnieszka Kowalczyk's contributions to the field of drug delivery through her numerous patents exemplify her commitment to advancing medical technology. With her innovative approach to integrin antagonists, she continues to pave the way for more targeted and effective treatments, thus playing a significant role in the evolution of therapeutic strategies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile